We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Boehringer Ingelheim has announced that the TROICA trial, a randomized, double-blind, placebo-controlled Phase III clinical study of the single-bolus thrombolytic Metalyse (tenecteplase) to assess the efficacy and safety of pre-hospital thrombolytic therapy in cardiac arrest of presumed cardiac origin, had been terminated.
GlaxoSmithKline (GSK) has submitted applications for both U.S. and European marketing approval for a new medicine to treat the symptoms of seasonal allergic rhinitis and perennial allergic rhinitis.
UCB has submitted a new drug application (NDA) to the FDA for Xyzal (levocetirizine dihydrochloride), a new prescription antihistamine for treatment of allergy symptoms.
Pharming Group announced that it has received a fast-track designation from the FDA for its recombinant human C1 inhibitor for the treatment of hereditary angioedema (HAE).
Callisto Pharmaceuticals has announced the expansion of its ongoing Phase I/IIa trial of Atiprimod to treat relapsed or refractory multiple myeloma patients to an additional clinical trial site: the University of Michigan Comprehensive Cancer Center.
Inspire Pharmaceuticals is initiating a Phase III trial to evaluate its drug candidate, denufosol tetrasodium inhaled solution, in patients with mild cystic fibrosis.